Author:
Takeshima Takao,Nakai Masami,Shibasaki Yoshiyuki,Ishida Miki,Kim Byung-Kun,Ning Xiaoping,Koga Nobuyuki
Abstract
Abstract
Background
Early onset of action has become recognized as an important efficacy feature of preventive migraine treatment, which can help overcome adherence issues commonly associated with older medications. Preventive treatments that target the calcitonin gene-related peptide (CGRP) or the CGRP receptor have been previously shown to provide early onset of action.
Methods
This subanalysis of primary endpoints of two separate phase 2b/3 studies sought to determine the onset of action of fremanezumab in Japanese and Korean patients with episodic migraine (EM) and chronic migraine (CM).
Results
In EM patients (n = 357), both fremanezumab quarterly and fremanezumab monthly led to greater reductions in weekly migraine days (days/week) than placebo from the first week after the initial injection and thereafter during the remainder of the study period. Similarly, CM patients (n = 571) had a greater reduction in headache days of at least moderate severity (days/week) with fremanezumab (total) than placebo. The percentage of patients with a migraine day (EM) or headache day at least moderate severity (CM) was lower in those treated with fremanezumab than placebo and this effect was apparent from as early as Day 2 (1 day after first injection).
Conclusions
These results suggest that fremanezumab has an early onset of action, as noted in previous post hoc analyses of anti-CGRP monoclonal antibodies.
Trial registration
ClinicalTrials.gov. NCT03303092, Registered 5 October 2017, NCT03303079, Registered 5 October 2017.
Funder
Otsuka Pharmaceutical Co., Ltd.
Publisher
Springer Science and Business Media LLC
Subject
Anesthesiology and Pain Medicine,Neurology (clinical),General Medicine
Reference31 articles.
1. GBD (2017) Disease and injury incidence and prevalence collaborators (2018) global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 392(10159):1789–1858
2. Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A et al (2016) Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clin Proc S0025-6196(16):00126–00129
3. D'Amico D, Grazzi L, Usai S, Leonardi M, Raggi A (2013) Disability and quality of life in headache: where we are now and where we are heading. Neurol Sci 34(Suppl 1):S1–S5
4. Ferracini GN, Dach F, Speciali JG (2014) Quality of life and health-related disability in children with migraine. Headache 54(2):325–334
5. Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ (2003) The family impact of migraine: population-based studies in the USA and UK. Cephalalgia 23(6):429–440
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献